Every Form 4 that Black Diamond Therapeutics, Inc. (BDTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BDTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDTX filings page.
Black Diamond Therapeutics, Inc. (symbol: BDTX) is the issuer of record for a Form 4 filing submitted to the SEC. Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics, Inc. (BDTX) director Ali Behbahani reported receiving 7,707 shares of common stock on September 18, 2026 as a grant under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy, in lieu of cash fees, valued using the $1.93 September 17, 2026 closing price.
Following this award, Behbahani holds 110,236 shares directly and has indirect exposure to 4,448,757 shares held by New Enterprise Associates 16, L.P., where he participates through related general partner entities and disclaims beneficial ownership of portions in which he has no pecuniary interest. No Rule 10b5-1 trading plan is reported.
Black Diamond Therapeutics, Inc. (BDTX) reported that director Raman Prakash acquired 6,801 shares of common stock on September 18, 2026 as a grant under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy, received in lieu of cash compensation, at a reference price of $1.93 per share based on the September 17, 2026 closing price. Following this equity award, Prakash directly holds 51,840 shares of Black Diamond Therapeutics common stock, and no Rule 10b5-1 trading plan is reported for this transaction.
Black Diamond Therapeutics director Ali Behbahani received a grant of stock options covering 40,000 shares of common stock at an exercise price of $1.71 per share. The options expire on June 25, 2036 and were granted as a compensation award, not an open-market purchase.
According to the terms, all 40,000 options will vest and become exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Behbahani continues to serve as a director through that date. After this grant, his directly held option position reported in this filing totals 40,000 options.
Black Diamond Therapeutics director Samarth Kulkarni received a grant of stock options covering 40,000 shares of common stock. These options have an exercise price of $1.71 per share and are held directly in his name.
The options vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, as long as he continues to serve through that vesting date. After this grant, he holds options to acquire 40,000 shares, and there are no open-market purchases or sales reported in this filing.
Black Diamond Therapeutics director Garry E. Menzel received a stock option award for 40,000 shares of common stock. The option has an exercise price of $1.71 per share and expires on June 25, 2036. It was granted as a compensation award rather than a market purchase or sale.
The option will vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, subject to his continued service through that date. Following this grant, he holds 40,000 option-based rights directly.
Black Diamond Therapeutics director Raman Prakash received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036. Following this grant, Prakash holds options for 40,000 underlying shares.
According to the vesting terms, the options will become fully exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, as long as he continues to serve the company through that vesting date.
Black Diamond Therapeutics director Kapil Dhingra received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036. All 40,000 options are reported as held directly following this award.
According to the grant terms, the options will vest and become exercisable in full on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Dhingra continues to serve through the vesting date. This is a compensation-related award, not an open-market purchase.
Black Diamond Therapeutics director Shannon Campbell received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.71 per share and expire on June 25, 2036.
According to the terms, the entire option grant will vest and become exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Campbell continues to serve through that date. Following this grant, Campbell holds options for 40,000 underlying shares directly.
Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Ali Behbahani received a grant of 8,961 shares of common stock at $1.66 per share. These shares were issued under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy, in which he elected stock instead of cash for annual board service.
After this award, Behbahani directly holds 102,529 shares of common stock. Separately, 4,448,757 shares are reported as indirectly held by New Enterprise Associates 16, L.P., where he is affiliated through general partner entities. He disclaims beneficial ownership of portions of those indirect holdings in which he has no pecuniary interest.
Raman Prakash reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Raman Prakash received 7,907 shares of common stock as equity compensation. The shares were granted in lieu of cash fees under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy at a reference price of $1.66 per share, based on the June 18, 2026 closing price. Following this award, Prakash directly holds 45,039 shares.
Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Ali Behbahani received a grant of 6,919 shares of common stock on March 20, 2026. The award was made under the company’s non-employee director compensation policy, as he elected to take stock instead of cash fees for his annual board service.
The grant was valued at $2.15 per share, based on the closing market price on March 19, 2026. After this award, Behbahani directly holds 93,568 common shares. The filing also reports 4,448,757 shares held indirectly through New Enterprise Associates 16, L.P., where he disclaims beneficial ownership for portions in which he has no pecuniary interest.
Raman Prakash reported acquisition or exercise transactions in this Form 4 filing.
Black Diamond Therapeutics director Raman Prakash received 6,105 shares of Common Stock as compensation. The shares were issued under the company’s non-employee director compensation policy, where he elected stock instead of cash for annual board service. The grant was valued at $2.15 per share, bringing his direct holdings to 37,132 shares.
Black Diamond Therapeutics, Inc. reports an option grant to senior management. Officer Erika Jones, who serves as Senior Vice President, Finance and Corporate Controller, was granted a stock option to purchase 200,000 shares of common stock at an exercise price of $2.57 per share on January 21, 2026.
According to the vesting terms, 25% of the shares subject to this option will vest and become exercisable on January 21, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on her continued service with the company. Following this grant, she holds 200,000 derivative securities (stock options) directly.
Black Diamond Therapeutics granted its Chief Operating Officer and General Counsel, Brent Hatzis-Schoch, a stock option for 250,000 shares of common stock on January 21, 2026. The option has an exercise price of $2.57 per share and is scheduled to expire on January 20, 2036.
According to the vesting terms, 25% of the option will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on his continued service. After this grant, he beneficially owns 250,000 derivative securities directly.
Black Diamond Therapeutics, Inc. reported that its Chief Scientific Officer, Elizabeth Buck, received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $2.57 per share and were granted on January 21, 2026, with an expiration date of January 20, 2036. According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, conditioned on her continued service. Following this grant, she holds 250,000 derivative securities directly.
Black Diamond Therapeutics, Inc. reported that its chief medical officer, Sergey Yurasov, received a grant of stock options covering 250,000 shares of common stock on January 21, 2026. The options have an exercise price of $2.57 per share and were awarded at no cost for the options themselves.
According to the vesting terms, 25% of the option shares will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments after that date, contingent on Dr. Yurasov’s continued service. Following this grant, he holds stock options for 250,000 derivative securities directly.
Black Diamond Therapeutics President and CEO Mark A. Velleca reported a new stock option grant. On January 21, 2026, he was awarded a stock option to buy 600,000 shares of Black Diamond Therapeutics common stock at an exercise price of $2.57 per share. According to the vesting terms, 25% of the shares under this option will vest and become exercisable on January 21, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, conditioned on his continued service with the company. Following this grant, he beneficially owns 600,000 derivative securities in the form of this option, held directly.
Black Diamond Therapeutics reported that a non-employee director received 5,208 shares of common stock as compensation for annual board service.
The shares were issued on December 12, 2025 under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director elected to take stock instead of cash fees.
The award was valued at $2.76 per share, based on the closing market price on December 11, 2025. Following this grant, the director beneficially owns 86,649 shares directly and has additional indirect interests in shares held by investment funds affiliated with New Enterprise Associates, while disclaiming beneficial ownership of portions in which there is no pecuniary interest.
Black Diamond Therapeutics reported that one of its non-employee directors acquired 4,665 shares of the company’s common stock on December 12, 2025, as reflected in a Form 4 insider trading report.
The shares were issued under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director elected to receive stock instead of cash for annual board service. The value was based on the $2.76 closing market price on December 11, 2025, and the director now beneficially owns 31,027 shares held directly.